Schering-Plough Licenses Intranasal Pleconaril For Common Cold
This article was originally published in The Pink Sheet Daily
Executive Summary
The product formulation from ViroPharma is in Phase II. The oral form of the drug, Sanofi's Picovir, received a "not approvable" letter in 2002 from FDA.
You may also be interested in...
Schering-Plough Will Eye Primary Care Acquisitions To Complement Vytorin, Zetia
CEO Hassan vows not to repeat mistakes of Schering's past by relying on the cholesterol agents to carry the business for the long-term. Bayer's oral Factor Xa inhibitor is a potential acquisition candidate, depending on how the antithrombotic fares in Phase III.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.